Recent advances in understanding the mechanism of action of bisphosphonates

Current Opinion in Pharmacology

Volumn 6, Issue 3, 2006, Pages 307-312

  Coxon, Fraser P ^a   Thompson, Keith ^a   Rogers, Michael J ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38; NE 10790; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PROTEIN CDC42; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAB PROTEIN; RAC PROTEIN; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BINDING AFFINITY; BONE MINERAL; BONE TURNOVER; CELL PROLIFERATION; CELL SURVIVAL; DRUG BLOOD LEVEL; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FLU LIKE SYNDROME; HUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRENYLATION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ACUTE-PHASE REACTION; ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ENZYME INHIBITORS; GERANYLTRANSTRANSFERASE; HUMANS; LYMPHOCYTE ACTIVATION; OSTEOCLASTS; OSTEOPOROSIS; PYRIDINES; T-LYMPHOCYTE SUBSETS;

EID: 33646383590     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.03.005     Document Type: Review

References (46)

1. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9 (2003) 2643-2658
2. Masarachia P., Weinreb M., Balena R., and Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 19 (1996) 281-290
3. Frith J.C., Monkkonen J., Blackburn G.M., Russell R.G., and Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12 (1997) 1358-1367
4. Frith J.C., Monkkonen J., Auriola S., Monkkonen H., and Rogers M.J. The molecular mechanism of action of the anti-resorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 44 (2001) 2201-2210
5. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Monkkonen J., Rogers M.J., Azhayev A., Vaananen H.K., and Hassinen I.E. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61 (2002) 1255-1262
6. van Beek E., Pieterman E., Cohen L., Lowik C., and Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264 (1999) 108-111
7. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., and Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373 (2000) 231-241
8. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., and Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235-242
9. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 2006, in press.
10. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA: Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006, in press.
11. Ebetino F.H., Francis M.D., Rogers M.J., and Russell R.G.G. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother 9 (1998) 233-243
12. Thompson K, Rogers MJ, Coxon FP, Crockett JC: Cytosolic entry of bisphosphonate drugs requires acidification of vesicles following fluid-phase endocytosis. Mol Pharmacol 2006, in press.
13. Frith J.C., and Rogers M.J. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18 (2003) 204-212
14. Takami M., Suda K., Sahara T., Itoh K., Nagai K., Sasaki T., Udagawa N., and Takahashi N. Involvement of vacuolar H(+)-ATPase in incorporation of risedronate into osteoclasts. Bone 32 (2003) 341-349
15. Staal A., Frith J.C., French M.H., Swartz J., Gungor T., Harrity T.W., Tamasi J., Rogers M.J., and Feyen J.H. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18 (2003) 88-96
16. Coxon F.P., Ebetino F.H., Mules E.H., Seabra M.C., McKenna C.E., and Rogers M.J. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37 (2005) 349-358
17. Schindeler A., and Little D.G. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 338 (2005) 710-716
18. ••].
19. Kavanagh K, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RGG, Oppermann U: The molecular mechanism of nitrogen-containing bisphosphonates as anti-osteoporosis drugs: crystal structure and inhibition of farnesyl pyrophosphate synthase. Proc Natl Acad Sci U S A 2006, in press. The authors of this and the previous article reported, independently of each other, the first X-ray crystal structure of human FPP synthase and identified the mode of inhibition of the enzyme by N-BPs and residues crucial for drug-protein interactions.
20. Martin M.B., Arnold W., Heath H.T., Urbina J.A., and Oldfield E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun 263 (1999) 754-758
21. Hosfield D.J., Zhang Y., Dougan D.R., Brooun A., Tari L.W., Swanson R.V., and Finn J. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 279 (2003) 8526-8529
22. Ebetino F.H., Roze C.N., McKenna C.E., Barnett B.L., Dunford J.E., Russell R.G.G., Mieling G.E., and Rogers M.J. Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. J Organomet Chem 690 (2005) 2679-2687
23. Thompson K., Rojas-Navea J., and Rogers M.J. Alkylamines cause Vγ9Vδ2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 107 (2006) 651-654
24. Szabo C.M., Matsumura Y., Fukura S., Martin M.B., Sanders J.M., Sengupta S., Cieslak J.A., Loftus T.C., Lea C.R., Lee H.J., et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem 45 (2002) 2185-2196
25. Coxon F.P., and Rogers M.J. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int 72 (2003) 80-84
26. Coxon F.P., Helfrich M.H., Larijani B., Muzylak M., Dunford J.E., Marshall D., McKinnon A.D., Nesbitt S.A., Horton M.A., Seabra M.C., et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 276 (2001) 48213-48222
27. Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP: Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42 and Rho GTPases. J Bone Miner Res 2006, in press. The authors demonstrate that N-BPs cause accumulation of active unprenylated Rho family GTPases in osteoclasts, raising the possibility that N-BPs might act by inappropriate stimulation, rather than inhibition, of small GTPase-dependent signalling pathways.
28. Allal C., Favre G., Couderc B., Salicio S., Sixou S., Hamilton A.D., Sebti S.M., Lajoie-Mazenc I., and Pradines A. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275 (2000) 31001-31008
29. Khwaja A., Dockrell M.E., Hendry B.M., and Sharpe C.C. Prenylation is not necessary for endogenous Ras activation in non-malignant cells. J Cell Biochem 97 (2006) 412-422
30. Vecchione C., and Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91 (2002) 173-179
31. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280 (2005) 34202-34209
32. Lerner E.C., Qian Y., Blaskovich M.A., Fossum R.D., Vogt A., Sun J., Cox A.D., Der C.J., Hamilton A.D., and Sebti S.M. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270 (1995) 26802-26806
33. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 Suppl 4 (2004) 3-13
34. Monkkonen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., and Monkkonen J. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147 (2006) 437-445
35. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., Wesolowski G., Russell R.G., Rodan G.A., and Reszka A.A. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96 (1999) 133-138
36. Halasy-Nagy J.M., Rodan G.A., and Reszka A.A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 29 (2001) 553-559
37. van Beek E.R., Cohen L.H., Leroy I.M., Ebetino F.H., Lowik C.W., and Papapoulos S.E. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33 (2003) 805-811
38. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., and Lo Cascio V. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41 (1987) 326-331
39. Kunzmann V., Bauer E., and Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340 (1999) 737-738
40. Thompson K., and Rogers M.J. Statins prevent bisphosphonate-induced γ,δ-T-cell proliferation and activation in vitro. J Bone Miner Res 19 (2004) 278-288. This study demonstrate that N-BPs activate γδ T cells indirectly through inhibition of FPP synthase and that statins can prevent this stimulatory effect of N-BPs on γδ T cells in vitro.
41. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., and De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197 (2003) 163-168. The authors show that Vγ9Vδ2 T cells recognize endogenous mevalonate metabolites that accumulate in N-BP-treated tumour cells in vitro.
42. Sanders J.M., Ghosh S., Chan J.M., Meints G., Wang H., Raker A.M., Song Y., Colantino A., Burzynska A., Kafarski P., et al. Quantitative structure-activity relationships for γδ T cell activation by bisphosphonates. J Med Chem 47 (2004) 375-384
43. Hewitt R.E., Lissina A., Green A.E., Slay E.S., Price D.A., and Sewell A.K. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood γδ T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139 (2005) 101-111
44. Boissier S., Ferreras M., Peyruchaud O., Magnetto S., Ebetino F.H., Colombel M., Delmas P., Delaisse J.M., and Clezardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 (2000) 2949-2954
45. Roelofs AJ, Hulley PA, Meijer A, Ebetino FH, Russell RGG, Shipman CM: Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells. Int J Cancer 2006, in press.
46. Lackner M.R., Kindt R.M., Carroll P.M., Brown K., Cancilla M.R., Chen C., de Silva H., Franke Y., Guan B., Heuer T., et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7 (2005) 325-336